ArticleFrontiers in immunology2021
Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 65 citations in OpenAlex.
- DSCC1 Identified as Promising Tumor Biomarker and Potential Therapeutic Target Through Comprehensive Multi-omics Analysis and Experimental Validation.Molecular biotechnology · 2026Article
- A bittersweet symphony: soluble mediator networks orchestrate melanoma plasticity and therapeutic adaptation.Frontiers in cell and developmental biology · 2026Review
- Analysis of Alternative Splicing Events in Melanoma and the Implications for Prognosis.Current molecular medicine · 2026Article
- UnveilingTranslational cancer research · 2025Article
- Identification of PIF1 as a Ferroptosis-Related Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.Applied biochemistry and biotechnology · 2025Article
- High Copy Number Variations Correlate with a Pro-Tumoral Microenvironment and Worse Prognosis in Acral Lentiginous Melanoma.International journal of molecular sciences · 2025Article
- Revealing tumor microenvironment communication through m6A single-cell analysis and elucidating immunotherapeutic potentials for cutaneous melanoma (CM).Journal of cancer research and clinical oncology · 2025Article
- Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.Heliyon · 2025Article
- CDKN2A, a key gene in copper-induced cell death model, influencing melanoma invasion and apoptosis.Discover oncology · 2025Article
- Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers.International journal of molecular sciences · 2025Review
- The role of mitophagy-related genes in prognosis and immunotherapy of cutaneous melanoma: a comprehensive analysis based on single-cell RNA sequencing and machine learning.Immunologic research · 2025Article
- Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization.Cancer biology & medicine · 2025Review
- Overexpression of CTLA-4 and fibronectin, and lower expression of CD137 (4-1BB) is associated with brain metastasis of primary skin melanomas. An analysis of local immune response by digital spatial profiling.Frontiers in immunology · 2025Article
- Metabolism of tumor infiltrating T cells.Frontiers in immunology · 2025Review
- An artificial intelligence-based model exploiting H&E images to predict recurrence in negative sentinel lymph-node melanoma patients.Journal of translational medicine · 2024Article
- Exploring the relationship between anal fistula and colorectal cancer based on Mendelian randomization and bioinformatics.Journal of cellular and molecular medicine · 2024Article
- Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1.Oncogene · 2024Article
- Article
- P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial Melanoma.Diagnostics (Basel, Switzerland) · 2024Article
- Tissue-resident memory T cell signatures from single-cell analysis associated with better melanoma prognosis.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tumor microenvironment (TME) involves infiltration of multiple immune cell subsets, which could influence the prognosis and clinical characteristics. The increasing evidence on the role of tumor-infiltrating lymphocytes (TILs) in primary and metastatic melanomas supports that the immune system is involved in the progression and outcomes of melanoma. However, the immune infiltration landscape in melanoma has not been systematically elucidated. Methods: In this study, we used CIBERSORT and ESTIMATE algorithms to analyze immune infiltration pattern of 993 melanoma samples. Then we screened differential expression genes (DEGs) related to immune subtypes and survival. The immune cell infiltration (ICI) score was constructed by using principal-component analysis (PCA) based on immune signature genes from DGEs. Gene set enrichment analysis (GSEA) was applied to explore high and low ICI score related pathways. Finally, the predictive ability of ICI score was evaluated in survival prognosis and immunotherapy benefit. Result: We identified three ICI clusters and three gene clusters associated with different immune subtypes and survival outcomes. Then the ICI score was constructed, and we found that high ICI score exhibited activated immune characteristics and better prognosis. High ICI score was significantly enriched in immune pathways and highly expressed immune signature genes. More importantly, we confirmed that melanoma patients with high ICI score had longer overall survival and rate of response to immunotherapy. Conclusion: We presented a comprehensive immune infiltration landscape in melanoma. Our results will facilitate understanding of the melanoma tumor microenvironment and provide a new immune therapy strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.